General
Preferred name
vonoprazan
Synonyms
TAK-438 (free base) ()
TAK-438 ()
TAK 438 ()
Vonoprazan Fumurate ()
TAK438 ()
Vonoprazan fumarate ()
Vonoprazan (fumarate) ()
Vonoprazan Fumarate (TAK-438) ()
Vocinti ()
Takecab ()
Voquezna ()
TAK-438 monofumarate ()
Vonoprazan monofumarate ()
P&D ID
PD071923
CAS
1260141-27-2
881681-00-1
881681-01-2
Tags
available
drug
Approved by
PMDA
First approval
2022
2014
Drug indication
Helicobacter infection
Gastroesophageal reflux disease
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCPRITION a potassium-competitive proton pump blocker for the treatment of acid-related disorders
DESCRIPTION Vonoprazan (TAK-438) is a first-in-class, potassium competitive acid blocker (P-CAB) class agent . It reduces gastric acid production via reversible inhibition of the gastric proton pump ATPase (a.k.a. gastric H+,K+-ATPase) . The compound appears to dock within the luminal vestibule of the proton pump's alpha subunit (ATP4A) and prevents K+ access to the ion binding domain, with a Ki of 3 nM for the wild type H+,K+-ATPase . Vonoprazan has a faster onset of action than widely used proton pump inhibitors (PPI), doesn't require acid-mediated activation and provides long-lasting inhibition (due to its slow dissociation rate) of the gastric H+,K+-ATPase . (GtoPdb)
DESCRIPTION Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori[1][2][3].
PRICE 29
PRICE 29
DESCRIPTION Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease[1][2].
DESCRIPTION Vonoprazan fumarate (TAK-438) is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase.
DESCRIPTION Vonoprazan is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+ ATPase with IC50 of 19 nM (pH 6.5), controls gastric acid secretion. It is used to treat acid-related diseases. It can be used for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori. It is a pyrrole derivative with a chemical structure that is completely different from the P-CABs developed to date in vitro. It inhibits basal gastric acid secretion in a dose-dependent manner, and the ID50 value is 1.26 mg/kg in vivo. It shows a potent and longer-lasting inhibitory effect on the histamine-stimulated gastric acid secretion in rats and dogs. It shows significant antisecretory activity through high accumulation and slow clearance from the gastric tissue. It is unaffected by the gastric secretory state. It was developed by Takeda and Otsuda together. It has been listed. (BOC Sciences Bioactive Compounds)
DESCRIPTION Vonoprazan (TAK-438 (free base)) is an orally active potassium-competitive acid blocker.Vonoprazan can be used for the treatment of gastroduodenal ulcer and reflux esophagitis (TargetMol Bioactive Compound Library)
DESCRIPTION Vonoprazan Fumarate (TAK438) , a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumarate (TAK438) inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5. (TargetMol Bioactive Compound Library)
Compound Sets
19
AdooQ Bioactive Compound Library
A11239
Axon Medchem Screening Library
1971
BOC Sciences Bioactive Compounds
vonoprazan-cas-881681-00-1-item-474886
Cayman Chemical Bioactives
24200
ChEMBL Approved Drugs
CHEMBL2079130
CHEMBL2064032
ChEMBL Drugs
CHEMBL2079130
CHEMBL2064032
Drug Repurposing Hub
DrugBank
DB11739
DrugBank Approved Drugs
DB11739
DrugCentral
4993
DrugCentral Approved Drugs
4993
DrugMAP
DMO6315
DrugMAP Approved Drugs
DMO6315
Guide to Pharmacology
11549
MedChem Express Bioactive Compound Library
HY-100007
HY-15295
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
tak-438
TargetMol Bioactive Compound Library
T8388
T21254
External IDs
44
Properties
(calculated by RDKit )
Molecular Weight
345.09
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
2.65
TPSA
63.99
Fraction CSP3
0.12
Chiral centers
0.0
Largest ring
6.0
QED
0.77
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
potassium-competitive acid
Proton Pump
ATP4A
PCA blocker
Potassium Channel
Bacterial
Indication
peptic ulcer disease (PUD)
MOA
potassium-competitive acid antagonist
Pathway
Anti-infection
Membrane Transporter/Ion Channel
Solubility
DMSO: ≥ 33 mg/mL
Source data